Antidepressant Market in the US 2015-2019
According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Depression can be recurrent, and can be severely debilitating for an individual. In patients with mild depression, the patient can be treated with medications, and in moderate or severe depression, a patient needs both medication and professional psychotherapy in terms of counseling. It has been reported by the WHO in 2008, that depression equally affects men and women, but women have a 50 percent higher tendency to get affected by depression than men. According to the CDC, depression can lead to adverse behavioral traits in an individual such as, alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, one out of every 10 people is affected with depression in the US. Major depressive disorder is among the most debilitating disorders in the US, and affects approximately 14.8 million adults in the country, aged 18 years and above, according to the NIMH in the US.
TechNavio's analysts forecast the Antidepressant market in the US to grow at a CAGR of [4.08] percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Antidepressant market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of depression. The Antidepressant market in the US is segmented based on the mechanism of action of the drugs used to treat depression, as illustrated below:
TechNavio Announces the Publication of its Research Report – Antidepressant Market in the US 2015-2019
TechNavio recognizes the following companies as the key players in the Antidepressant Market in the US: Actavis plc, Eli Lilly and Co., GlaxoSmithKline plc, Otsuka Pharmaceutical Co. Ltd. and Pfizer Inc.
Other Prominent Vendors in the market are: Abbott Laboratories, Astrazeneca, Aurobindo Pharma, Bristol-Myers Squibb, Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin, Novartis, Pierre Fabre, Shire, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals.
Commenting on the report, an analyst from TechNavio’s team said: “Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which in turn can result in an increase in the overall consumption of medicines.”
According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market.
Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US.
Actavis , Eli Lilly and Company, GlaxoSmithKline , Otsuka Pharmaceutical , Pfizer , Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Bristol-Myers Squibb, Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin, Novartis, Pierre Fabre , Shire , SomersetPharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals